On February 12, 2014, Ariosa Diagnostics, Inc. obtained licensure approval from New York for Harmony TM noninvasive prenatal testing (NIPT) (1) . This testing uses fetal genetic material obtained from a maternal blood sample to carry out genetic sequencing in order to detect certain genetic conditions during pregnancy based on the discovery of free fetal DNA in maternal plasma (2) . NIPT offers advantages compared to traditional invasive procedures. NIPT can be performed with a maternal blood sample, which means that it is not associated with a risk of miscarriage. This aspect also means that NIPT is better suited to screening (3) . Therefore, NIPT is likely to serve as a tool to screen for genetic defects in fetuses without risking a miscarriage. Since 80% of rare diseases are genetic diseases (4), any method that can help to detect genetic conditions can be seen as a possible way to respond to rare diseases. Earlier diagnosis and treatment of diseases like phenylketonuria can mean a better prognosis (5) (6) (7) . Therefore, prenatal testing is more likely to help improve the treatment of rare diseases than newborn testing, and this is especially true for rare diseases (5, 6, 8) . As mentioned earlier, NIPT avoids the risk of miscarriage associated with traditional invasive procedures, and this aspect means that NIPT is more likely to detect rare genetic diseases early on. Currently, NIPT is focused on detecting genetic diseases such as Trisomy 21, 18, and 13, Turner syndrome, 22q11.2 deletion syndrome, and 1p36 deletion syndrome, all of which are rare genetic diseases.
China is a country with the world's largest population of patients with rare diseases (7), and China faces huge challenges in responding to rare diseases. Faced with these challenges, China has adopted several strategies to improve the healthcare of patients with rare diseases, including reimbursement of medical expenses for children with congenital heart disease and leukemia (9) and a new born screening program (5, 10) . As NIPT has matured, this technology has been marketed Commentary (11, 12) February 9, 2014 (23) . This move indicates that the Chinese government has begun overseeing the market for NIPT-related products. On March 3, 2014, the NHFPC issued a "Notice regarding approval procedures for a pilot project involving clinical use of high-throughput genetic sequencing" (24) to improve the system for registration of genetic sequencing in China. These notices are mainly focused on criteria and authority for registration. Regulations on how NIPT should be performed and maintaining its quality are still lacking.
The US government has experience overseeing NIPT that may be helpful: i) Strict registration is needed to ensure the quality of NIPT. In the US, a developer/ manufacturer of an NIPT test must first obtain a 510(k) premarket notification (510k) from the US Food and Drug Administration (FDA) (25) Over 100,000
Ref. (27) . And study has also indicated that LDTs and CLIA certification can improve innovation (28) .
Research into NIPT in China is still lacking. With a new technology like NIPT, recommendations or official opinions should be provided by academic societies to give guidance on how NIPT should be used and where the cutting edge of research lies. As of this writing, however, there are no such recommendations or opinions in China been reviewed. Several opinions on NIPT have been issued by academic committees in places like the U.S., Europe, Canada, and Japan from December 2012 to May 2013 (29, 30) . These opinions include statements on the clinical use of NIPT, the limitations of current NIPT, who is eligible to undergo NIPT, and guidelines for medical staff. In order to enhance research into NIPT in China, academic societies of geneticists, obstetricians, gynecologists and specialists in maternal-fetal medicine should provide committee opinions that are suited to the current situation in China.
NIPT has potential in terms of detecting rare genetic diseases and it has been used in many countries and regions. China is a country with the world's largest population of patients with rare diseases patients, and China has implemented NIPT since 2010. However, NIPT oversight and research in China are still lacking. With the improvement of these aspects, NIPT may offer promise in terms of the early detection of rare diseases.
